Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain.
Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain; Department of Dermatology, Hospital de Figueres, Fundació Salut Empordà, Figueres, Spain.
Actas Dermosifiliogr. 2023 Oct;114(9):784-801. doi: 10.1016/j.ad.2023.06.012. Epub 2023 Jun 16.
JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases. Four molecules have been approved for dermatological use: upadacitinib, baricitinib, abrocitinib and topical ruxolitinib. Off-label prescriptions for other dermatological conditions have been reported. We conducted a narrative review of the literature to assess the long-term safety profile of currently approved JAK inhibitors in dermatology, and their off-label use in skin disorders. We performed literature searches with Pubmed and Google Scholar from January 2000 to January 2023, using the keywords "Janus kinase inhibitors", "JAK inhibitors", "off-label", "dermatology", "safety", "adverse events", "ruxolitinib", "upadacitinib", "abrocitinib" and "baricitinib". Our search yielded a total of 37 dermatological disorders with studies supporting the use of these JAK inhibitors. Preliminary studies indicate that JAK inhibitors generally have a favorable safety profile and can be considered as an option in many dermatological disorders.
JAK 抑制剂针对参与各种炎症性疾病的特定炎症细胞因子。有四种分子已被批准用于皮肤科用途：乌帕替尼、巴瑞替尼、阿布昔替尼和局部罗替尼。据报道，其他皮肤科疾病也有超适应证处方。我们对文献进行了叙述性综述，以评估目前批准用于皮肤科的 JAK 抑制剂的长期安全性概况，以及它们在皮肤疾病中的超适应证使用。我们使用 Pubmed 和 Google Scholar 从 2000 年 1 月到 2023 年 1 月进行了文献检索，使用的关键词是“Janus 激酶抑制剂”、“JAK 抑制剂”、“超适应证”、“皮肤科”、“安全性”、“不良反应”、“罗替尼”、“乌帕替尼”、“阿布昔替尼”和“巴瑞替尼”。我们的搜索共产生了 37 种皮肤病，这些疾病的研究支持使用这些 JAK 抑制剂。初步研究表明，JAK 抑制剂通常具有良好的安全性，可被视为许多皮肤科疾病的一种选择。
